-
-
-
-
-
-
-
Verrica Pharmaceuticals Inc. (VRCA) Tops Q3 EPS by 21c
-
-
-
-
-
-
-
Verrica Pharmaceuticals (VRCA) Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment
-
-
-
-
-
-
-
Verrica (VRCA) Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Confer
-
-
-
-
-
-
-
Verrica Pharmaceuticals (VRCA) PT Lowered to $10 at TD Cowen
-
-
-
-
-
-
412,756 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

